http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-109931-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_872dd7cd609eb2a937dcfd303d521798 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C2601-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C2601-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C2603-94 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C2601-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C2602-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C2601-16 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D271-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D205-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D215-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-41 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D277-64 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D277-62 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-397 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D239-42 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-427 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-428 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4196 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-422 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D257-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P21-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4427 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C235-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D277-44 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-506 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D239-72 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-14 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D257-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P21-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4709 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4427 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-165 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D417-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D417-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D205-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D417-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-397 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D413-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-41 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C235-40 |
| filingDate | 2017-10-11^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7ff3ee7fc963fe4211f09b2b5e5ed015 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_deb4e45f8f168c542f26d086c6549cad http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8fd9b2116472092042d05fd082988c8b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cea9dc7f99d3119f54dfc73eed37ea07 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e35271493492a66b62c17bb4a8c22051 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_71c49dad7f80303942795794e31cbc68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_47036679d48025cd0fa525e444ba2220 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fd27ae9bb6dde762cb0da41870ceb6ef |
| publicationDate | 2019-02-06^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-109931-A1 |
| titleOfInvention | INHIBITING COMPOSITE OF THE PROSTAGLANDINA D SINTASA HEMATOPOYÉTICA (H-PGDS), PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND USE OF THE COMPOUND TO MANUFACTURE A MEDICINAL PRODUCT |
| abstract | A hematopoietic prostaglandin D synthase (H-PGDS) inhibitor compound that is represented by the formula (1), wherein: X is selected from: carbon and nitrogen; And it is selected from: hydrogen and CH₃; Y¹ is absent or CH₃; Z is NH or O; a is 0 or 1; R is selected from: O, NH, CH₂ and halogen substituted C₁ alkyl; R¹ is selected from: aryl, aryl substituted 1 to 4 times with Rᵃ, heteroaryl, heteroaryl substituted 1 to 4 times with Rᵃ, bicycloheteroaryl, and bicycloheteroaryl substituted 1 to 4 times with Rᵃ; R² is selected from: O and S; R³ is selected from: aryl, aryl substituted 1 to 4 times with Rᵇ, cycloalkyl, cycloalkyl substituted 1 to 4 times with Rᵇ, heterocycle, heterocycle substituted 1 to 4 times with Rᵇ, heteroaryl, heteroaryl substituted 1 to 4 times with Rᵇ, bicycloheteroaryl, and bicycloheteroaryl substituted 1 to 4 times with Rᵇ; each Rᵃ is independently selected from: fluoro, chloro, bromo, iodo, -OH, C₁₋₆ alkyl, C₁₋₆ alkyl substituted with 1 to 5 substituents independently selected from: fluoro, chloro, bromo, iodo, C₁₋₄ alkyloxy, -OH, C₁₋₄ alkyl, oxo, -COOH, -NO₂, -NH₂ and -CN, cyano, -O-C₁₋₆ alkyl, -O-C₁₋₆ alkyl substituted with 1 to 5 substituents independently selected from: fluoro , chlorine, bromine, iodine, C₁₋₄ alkyloxy, -OH, C₁₋₄ alkyl, oxo, -COOH, -NO₂, -NH₂ and -CN, -C (O) O-C₁₋₆ alkyl, and -C ( O) O-C₁₋₆ alkyl substituted 1 to 5 times with fluoro; each Rᵇ is independently selected from: cyano, fluoro, chloro, bromo, iodo, C₁₋₆ alkyl, Rᵉ, -O-C₁₋₆ alkyl, -ORᵉ, oxo, hydroxyl, cycloalkyl, cycloalkyl substituted 1 to 4 times with Rᶠ , amino, -NHRˣ, where Rˣ is selected from aryl, heteroaryl, cycloalkyl, heterocycloalkyl, -O-C₁₋₆ alkyl, -O-C₁₋₆ alkyl substituted with 1 to 6 substituents independently selected from: fluoro, oxo, and -OH, C₁₋₆ alkyl, and C₁₋₆ alkyl substituted with 1 to 6 substituents independently selected from: fluoro, oxo, -OH, -OC₁₋₆alkyl, -COOH, -NH₂, -NH-cycloalkyl, and -CN , heteroaryl, heteroaryl substituted 1 to 4 times with Rᶠ, heterocycle, heterocycle substituted 1 to 4 times with Rᶠ, -SO₂H, and -SO₂-C₁₋₆ alkyl; each Rᶠ is independently selected from: fluoro, chloro, bromo, iodo, C₁₋₆ alkyl, Rᵉ, oxo, -OH, amino, -NHRˣ¹, where Rˣ¹ is selected from aryl, heteroaryl, cycloalkyl, heterocycloalkyl, C₁₋₆ alkyl, and C₁₋₆ alkyl substituted with 1 to 6 substituents independently selected from: fluoro, oxo, -OH, -O-C₁₋₆ alkyl, -COOH, -NH₂, and -CN, -NRˣ²Rˣ³, where Rˣ² and Rˣ³ is selected one independently of: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, C₁₋₆ alkyl, and C₁₋₆ alkyl substituted with 1 to 6 substituents independently selected from: fluoro, oxo, -OH, -COOH, -NH₂, and -CN, nitro , and cyano, and each Rᵉ is independently selected from: C₁₋₆ alkyl substituted with 1 to 9 substituents independently selected from: fluoro, chloro, bromo, iodo, C₁₋₆ alkyl, -O-C₁₋₆ alkyl, -O- C₁₋₆ alkyl substituted with 1 to 6 substituents independently selected from: fluoro, oxo, -OH, -COOH, -NH₂, -CN, and phenyl, oxo, = N, hydroxyl, amino, -NHRˣˣ, or = NRˣˣ, where Rˣˣ is selected from aryl, heteroaryl, cycloalkyl, heterocycloalkyl, cyano, C alquilo alkyl ₋₆, and C₁₋₆ alkyl substituted with 1 to 6 substituents independently selected from: fluoro, oxo, -OH, -COOH, -O-C₁₋₅ alkyl, -O-C₁₋₅ alkyl substituted 1 to 6 times with fluoro, -NRˣˣ¹Rˣˣ², where Rˣˣ¹ and Rˣˣ² are each independently selected from: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, C₁₋₆ alkyl, and C₁₋₆ alkyl substituted with 1 to 6 substituents independently selected from: fluoro, oxo, -OH , -COOH, -NH₂, and -CN, aryl, aryl substituted 1 to 4 times with Rˣˣ³, where Rˣˣ³ is selected from: fluoro, chloro, bromo, iodo, C₁₋₆ alkyl, C₁₋₆ alkyl substituted with 1 to 6 substituents independently selected from: fluoro, oxo, -OH, -COOH, -NH₂, and -CN, -O-C₁₋₅ alkyl, and -O-C₁ alkyl ₆ substituted with 1 to 6 independently substituents selected from: fluoro, oxo, -OH, -COOH, -NH₂, and -CN, cycloalkyl, cycloalkyl substituted 1 to 4 times with Rˣˣ⁴, where Rˣˣ⁴ is selected from: fluoro, chloro, bromine, iodine, C₁₋₆ alkyl, C₁₋₆ alkyl substituted with 1 to 6 substituents independently selected from: fluoro, oxo, -OH, -COOH, -NH₂, and -CN, -O-C₁₋₅ alkyl, and - O-C₁₋₆ alkyl substituted with 1 to 6 independently substituents selected from: fluoro, oxo, -OH, -COOH, -NH₂, and -CN, nitro, and cyano; or one of its pharmaceutically acceptable salts. The compounds described may be useful in the treatment of Duchenne muscular dystrophy. Pharmaceutical compositions comprising the compounds described and use of the compounds to make a medicament. |
| priorityDate | 2016-10-13^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Showing number of triples: 1 to 92 of 92.